急性视神经炎血清CXCL12、血小板源性生长因子及CXCL14水平与疾病转归  

Serum level of CXCL12,platelet-derived growth factor,CXCL14 in acute optic neuritis and its association with prognosis

作　　者：刘子豪 姜兆财[2] 魏世辉[3] 陈霆隽[3] 

机构地区：[1]北京市中医药大学附属东直门医院眼科,北京100700 [2]北京市隆福医院眼科,北京100010 [3]中国人民解放军总医院眼科,北京100853

出　　处：《中国眼耳鼻喉科杂志》2015年第3期155-162,共8页Chinese Journal of Ophthalmology and Otorhinolaryngology

摘　　要：目的对视神经炎(ON)及相关脱髓鞘疾病进行血清趋化因子12(CXCL12)、血小板源性生长因子(PDGF)、趋化因子14(CXCL14)浓度检测,分析不同疾病类型及时期各项因子的变化规律。方法采集就诊ON及相关脱髓鞘疾病患者的静脉血,并根据疾病种类及病程进行分组。用酶联免疫吸附试验(ELISA)对血液样本中CXCL12、PDGF及CXCL14的浓度进行定量检测。结果 1血清CXCL12检测结果:健康对照组(HC)的浓度为(0.207±0.150)ng/m L;急性期视神经炎(AON)组的浓度为(0.136±0.076)ng/m L;缓解期视神经炎(CON)组的浓度为(0.431±0.276)ng/m L;急性期视神经脊髓炎谱系疾病(ANMOSDs)组的浓度为(0.281±0.257)ng/m L;缓解期视神经脊髓炎谱系疾病(CNMOSDs)组的浓度为(0.270±0.132)ng/m L;视神经脊髓炎(NMO)组的浓度为(0.498±0.221)ng/m L;多发性硬化(MS)组的浓度为(0.439±0.174)ng/m L。2血清PDGF检测结果:HC组的浓度为(40.944±14.677)pg/m L;AON组的浓度为(25.771±5.094)pg/m L;CON组的浓度为(34.359±4.567)pg/m L;ANMOSDs组的浓度为(32.589±8.957)pg/m L;CNMOSDs组的浓度为(38.805±10.449)pg/m L;NMO组的浓度为(48.982±12.985)pg/m L;MS组的浓度为(50.498±6.322)pg/m L。3血清CXCL14检测结果:HC组的浓度为(2.149±1.783)ng/m L;AON组的浓度为(1.312±1.127)ng/m L;CON组的浓度为(4.740±2.281)ng/m L;ANMOSDs组的浓度为(2.111±1.351)ng/m L;CNMOSDs组的浓度为(2.127±1.739)ng/m L;NMO组的浓度为(7.096±5.198)ng/m L;MS组的浓度为(2.409±1.009)ng/m L。结论 1在ON的急性期,CXCL12、PDGF、CXCL14的血清浓度降低,而随着疾病的恢复,各因子浓度升高,可能略高于正常人水平。2在NMOSDs的急性期和缓解期,CXCL12和CXCL14血清浓度差异无统计学意义,与正常血清浓度差异也无统计学意义。PDGF血清浓度在急性期降低,缓解期升高,但始终低于正常人水平。3急性期的NMO和MS,CXCL12浓度均高于正常人水平。非急性期的NMO患者,CXCL14浓度高于正常人。4NMOSDs和NMOObjective To detect the serum level of chemokine 12 （CXCL12）, platelet-derived growth factor （PDGF）, and chemokine 14（CXCL14） in optic neuritis （ON） as well as other demyelination diseases, and to analyze the differences of these factors. Methods Venous blood of patients with ON and other demyelination diseases were collected and divided into several groups. Enzyme-linked immunosorbent assay was used to measure the serum level of CXCL12, PDGF and CXCL14. Results （1）The serum level of CXCL12 were 0.207 ± 0. 150 ng/mL in healthy control group（HC）, 0. 136±0.076 ng/mL in acute optic neuritis group（AON）, 0. 431 ±0. 276 ng/mL in catabatic optic neuritis group （ CON）, 0. 281 ± 0. 257 ng/mL in acute neuromyelitis optica spectrum diseases group （ANMOSDs）, 0. 270 ± 0. 132 ng/mL in catabatic neuromyelitis optica spectrum diseases group（ CNMOSDs）, 0.498 ± 0.221 ng/mL in neuromyelitis optica group（NMO）, and 0.439 ± 0. 174 ng/mL in multiple sclerosis group （MS）. （2）The serum level of PDGF were 40.944 ± 14.677 pg/mL in HC group, 25.771 ±5.094 pg/mL in AON group, 34.359 ±4. 567 pg/mL in CON group, 32.589 ± 8.957 pg/mL in ANMOSDs group, 38. 805 ± 10.449 pg/mL in CNMOSDs group, 48. 982 ±12.985 pg/mL in NMO group, and 50.498 ±6.322 pg/mL in MS group. （3）The serum level of CXCLI4 were 2. 149 ± 1. 783 ng/mL in HC group, 1. 312 ± 1. 127 ng/mL in AON group, 4.740 ±2.281 ng/mL in CON group, 2. 111 ± 1. 351 ng/mL in ANMOSDs group, 2. 127 ± 1. 739 ng/mL in CNMOSDs group, 7. 096 ± 5. 198 ng/mL in NMO group, and 2.409 ± 1. 009 ng/mL in MS group. Conchtsions （1）The serum level of CXCL12, PDGF and CXCL14 decrease in AON group, and increase even higher than that in HC group as symptom recovering. （2）The serum level of CXCL12 and CXCL14 have no significant distinction in different stages of NMOSDs. The serum level of PDGF is low in acute stage and high in eatabatie stage, but is lower than that in HC group all the time. （3）The serum level of CXCL12 in non-a

关 键 词：视神经炎 脱髓鞘疾病 趋化因子12 血小板源性生长因子 趋化因子14 

分 类 号：R774.61[医药卫生—眼科]